Related Experiment Video
Updated: May 30, 2026
07:19
Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique
Published on: February 7, 2025
New topics in bradykinin research
1Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité- Universitätsmedizin, Berlin, Germany. Marcus.Maurer@charite.de
Allergy
|August 24, 2011
Summary
Bradykinin contributes to allergic inflammation and angioedema by affecting blood pressure and vascular permeability. Understanding bradykinin receptor blockers may offer new therapeutic options for allergic conditions.
Area of Science:
- Immunology and Pharmacology
- Allergic Inflammation Research
Background:
- Bradykinin plays a significant role in allergic inflammation and the pathogenesis of allergic conditions.
- It interacts with endothelial B(1) and B(2) receptors, influencing physiological effects like blood pressure and vascular permeability.
Purpose of the Study:
- To review the current understanding of bradykinin's role in nonallergic angioedema.
- To explore bradykinin's potential as a therapeutic target for conditions managed by allergists and emergency physicians.
Main Methods:
- Literature review of existing research on bradykinin's function and receptor interactions.
- Analysis of bradykinin's involvement in inflammatory pathways and associated symptoms.
Main Results:
- Bradykinin is associated with decreased blood pressure, increased vascular permeability, vasodilation, hyperthermia, edema, and pain.
- Bradykinin also exhibits antithrombogenic, antiproliferative, and antifibrogenic effects.
Conclusions:
- Bradykinin is a key mediator in allergic inflammation and angioedema.
- Development of bradykinin receptor blockers presents novel therapeutic avenues requiring further investigation.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Acute Inflammation III: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:18Dysrhythmias IV: Characteristics of Bradyarrhythmias
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...